Epitalon is not approved by the U.S. FDA for human use and is not lawful to administer to humans. Where it is offered for sale in the U.S., it is sold only as a 'Research Use Only' laboratory chemical, not as a medicine.
Status as of July 14, 2026
Epitalon carries no validated prescribing information because it is not an approved drug in any major regulatory jurisdiction, so the honest bottom line is that every dosing figure attached to it is a description of what has been reported, not a clinical standard. The numbers in circulation trace to published research reports, early clinical work conducted primarily in Russia, and informal user practice, and none of it reflects the controlled dose-ranging trials that underpin approved medicines. The peptide is typically supplied as a lyophilized powder that must be reconstituted before administration, and reported protocols vary widely in amount, frequency, and cycle length.
Epitalon has no approved prescribing information, and every dosing figure in circulation, commonly around 5 to 10 milligrams per day over 10-to-20-day injected cycles, derives from research reports or informal practice rather than a validated clinical standard.
The dosing numbers circulated for Epitalon cluster loosely rather than converging on a single standard, and the most important distinction the record blurs is between a per-day amount and a whole-course total, which are sometimes reported interchangeably. Treatment is almost always framed as an intermittent cycle rather than continuous use, and much of what circulates originates in informal practice and vendor-adjacent write-ups rather than controlled dose-ranging studies.
The most frequently repeated Epitalon figure is roughly 5 to 10 milligrams per day across a 10-to-20-day cycle, though reported amounts span from a few milligrams to the low tens and no single figure is treated as canonical.
Injection dominates the Epitalon literature, and the choice between routes reflected in reported practice tracks convenience and convention more than any validated pharmacokinetic evidence. Because the compound is unapproved, none of these routes carries the bioavailability characterization that would normally accompany an approved injectable.
Injection, both intramuscular and subcutaneous, is the route behind essentially all reported Epitalon dosing figures, while oral delivery is considered impractical due to proteolytic breakdown and intranasal use rests mostly on extrapolation from related peptides.
The core reason no authoritative dosing standard exists is that Epitalon has not been approved as a drug by the major regulatory agencies, and approval is the process through which a validated dose normally emerges. Without that pipeline there is no official label, no standardized concentration or purity requirement, and no sanctioned schedule, which is why the figures in circulation vary so widely.
Because Epitalon has never been approved by a major regulatory agency, it carries no official label, standardized concentration, or sanctioned schedule, so any dose attached to it describes what has been reported rather than what is established as safe or effective.
Reconstitution is described in the practice literature as turning the dry, freeze-dried peptide into an injectable solution by adding a measured volume of liquid to the vial, where that volume sets the final concentration. Contamination is the central hazard of the step, since every needle entry and every surface the diluent touches is an opportunity to introduce microbes into a solution that will be injected.
Reported handling describes reconstituting lyophilized Epitalon with bacteriostatic water introduced slowly down the vial wall rather than shaken, with the added volume setting the final concentration and contamination control treated as the central hazard.
Once a peptide is dissolved it becomes chemically and biologically more vulnerable than it was as a dry solid, because water enables the hydrolysis, oxidation, and microbial growth that the lyophilized state largely prevents. The storage figures reported for the reconstituted material function as rules of thumb rather than validated shelf-life data, since no controlled stability study stands behind them.
| Property | Lyophilized powder | Reconstituted solution |
|---|---|---|
| Stability | Far more forgiving | Chemically and biologically vulnerable |
| Storage | Refrigerated or frozen, extended periods | ~2 to 8 C, protected from light and freeze-thaw |
| Usable window | Long, reported in months | Weeks, per reported rule of thumb |
| Discard cues | Rarely applicable while dry | Cloudiness, particulates, discoloration |
Reconstituted Epitalon is generally reported as kept near 2 to 8 degrees Celsius and usable for a window measured in weeks, while the lyophilized powder tolerates extended refrigerated or frozen storage, though none of these figures rests on a validated stability study.
The honest starting point is that Epitalon's safety profile in humans is poorly characterized, so the most important risk is the one that is hardest to see: the absence of the large, long-term data that would reveal uncommon or delayed harms. Layered on top of that biological uncertainty are the practical hazards of injection and the sourcing risks of an unapproved compound that escapes pharmaceutical manufacturing oversight.
Epitalon's human safety profile is poorly characterized, with early adverse-event reporting drawn from small studies never designed to detect rare or long-term harms, so no reported dose can be called safe on the existing evidence.
The comparison between injectable and intranasal Epitalon is really a comparison between a well-trodden but invasive route and a convenient but poorly documented one. The decisive difference is the strength-of-evidence gap, since the injectable route at least connects to the older clinical reports while the intranasal route rests largely on extrapolation from other peptides.
| Criterion | Injectable | Intranasal |
|---|---|---|
| Evidence base | Behind essentially all reported figures | Largely extrapolated from other peptides |
| Systemic delivery | More direct and predictable | Incomplete and variable absorption |
| Dosing implication | Basis of the reported amounts | Would need a larger, uncharacterized amount |
| Invasiveness | Needle, with infection risk | Needle-free |
The injectable route carries the deeper evidence base and more predictable delivery behind nearly all reported Epitalon figures, whereas intranasal delivery trades needle-free convenience for incomplete, variable absorption with no reliable conversion factor, and neither route is validated.
Protocol structure for Epitalon is shaped less by settled pharmacology and more by convention, practical constraints, and the design of the early studies. The strongest single force is inherited convention: much of what circulates is copied forward from prior reports and community practice rather than rebuilt from fresh dose-response evidence, which is precisely why the protocols carry an air of specificity the underlying data does not support.
Epitalon dosing protocols are shaped more by inherited convention, early-study design, and peptide stability limits than by controlled dose-response evidence, which is why they carry an air of specificity the underlying data does not actually support.
Educational use only. This article describes what the published scientific and clinical literature reports about Epitalon. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
